ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
17 announcements with these filters
JHS Svendgaard filed its quarterly Regulation 32 statement on 2024 preferential issue proceeds. Fund allocation shifted toward capex after shareholder approval; no quarter deviation reported.
JHS Svendgaard Laboratories appointed Mr. Pardeep Kumar Bhardwaj as a Non-Executive Independent Director, effective 2 November 2026, for five years, subject to shareholder approval. Board committee compositions were also reconstituted.
JHS Svendgaard Laboratories Ltd reported revenue from operations of ₹21.8 Cr (-2.2% YoY) and net profit of ₹0.5 Cr for Q2 FY27.
JHS Svendgaard Laboratories has intimated a Board meeting on 2 November 2026 to approve un-audited Q1/H1 FY27 results. Trading window closed from 1 October 2026.
JHS Svendgaard Laboratories Ltd has filed its quarterly shareholding pattern under Regulation 31(1)(b) of SEBI LODR Regulations for the quarter ended September 30, 2026.
JHS Svendgaard Laboratories held its 22nd Annual General Meeting on September 26, 2026, transacting business related to financial statements and director appointment.
JHS Svendgaard Labs filed a Reg 36(1)(b) letter sending web-links and QR codes for its 2025-26 Annual Report to unregistered shareholders. No transaction, board decision, or business event is involved.
JHS Svendgaard Laboratories Ltd will hold its 22nd Annual General Meeting on September 26, 2026. Shareholders will consider financial statements and director re-appointment.
JHS Svendgaard Laboratories Limited has filed its Integrated Annual Report for the Financial Year 2025-26, including notice for the 22nd Annual General Meeting.
JHS Svendgaard Laboratories Ltd reported revenue from operations of ₹30.4 Cr (+29.4% YoY) and net profit of ₹1.1 Cr (+0.0% YoY) for Q1 FY27.
JHS Svendgaard Laboratories has scheduled a board meeting for August 11, 2026. The board will consider and approve unaudited financial results for the quarter ended June 2026.
JHS Svendgaard Laboratories announced the conclusion of its remote e-voting process for the postal ballot on July 29, 2026. The Scrutinizer's report is awaited.
JHS Svendgaard Laboratories seeks member approval via postal ballot to reallocate Rs.30 Crore raised from its preferential issue. The vote runs from 30 June to 29 July 2026.
JHS Svendgaard Laboratories' board approved variations in using preferential issue proceeds. Total funds of ₹3.00 Crore will be redeployed for capital expenditure and growth.
JHS Svendgaard Laboratories Ltd reported revenue from operations of ₹32.7 Cr (+29.8% YoY) and a net loss of ₹3.6 Cr for Q4 FY26.
JHS Svendgaard Laboratories reported its audited financial results for the year ended March 31, 2026. The filing includes standalone and consolidated statements with unmodified audit opinions.
JHS Svendgaard Laboratories scheduled a board meeting for May 26, 2026, to approve audited financial results. The trading window remains closed until May 28, 2026.